NCT03311828View on ClinicalTrials.gov

Copper 64Cu-DOTA-Daratumumab Positron Emission Tomography in Diagnosing Patients With Relapsed Multiple Myeloma

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

February 21, 2018

Primary Completion Date

January 22, 2020

Study Completion Date

June 5, 2023

Conditions
Recurrent Plasma Cell MyelomaPlasma Cell MyelomaSecondary Amyloidosis
Interventions
BIOLOGICAL

Daratumumab

Given IV

DRUG

Imaging Agent

Given Copper 64Cu-DOTA-daratumumab IV

PROCEDURE

Positron Emission Tomography

Undergo PET

OTHER

Pharmacological Study

Correlative studies

Trial Locations (1)

91010

City of Hope Medical Center, Duarte

All Listed Sponsors
lead

City of Hope Medical Center

OTHER

NCT03311828 - Copper 64Cu-DOTA-Daratumumab Positron Emission Tomography in Diagnosing Patients With Relapsed Multiple Myeloma | Biotech Hunter | Biotech Hunter